Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors

2019 ◽  
Vol 120 (8) ◽  
pp. 1311-1317 ◽  
Author(s):  
Yosuke Kasai ◽  
Kelly Mahuron ◽  
Kenzo Hirose ◽  
Carlos U. Corvera ◽  
Grace E. Kim ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Prognostic Impact ◽  
Mesenteric Mass

scholarly journals Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 504
Author(s):  
Fiona Ohlendorf ◽  
Rudolf Werner ◽  
Christoph Henkenberens ◽  
Tobias Ross ◽  
Hans Christiansen ◽  
...  
Keyword(s):  
Treatment Response ◽  
Neuroendocrine Tumors ◽  
Radionuclide Therapy ◽  
Somatostatin Receptor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Tumor Burden ◽  
Inflammatory Biomarkers ◽  
Whole Body ◽  
Prognostic Impact ◽  
Peptide Receptor

Tumor microenvironment inflammation contributes to the proliferation and survival of malignant cells, angiogenesis, metastasis, subversion of adaptive immunity, and reduced treatment response. We aimed to evaluate the early predictive and prognostic significance of markers of systemic inflammation in patients receiving somatostatin-receptor targeted peptide receptor radionuclide therapy (PRRT). This retrospective observational cohort study included 33 patients with advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) treated with PRRT. Pretreatment blood-based inflammatory biomarkers, e.g., Creactive protein levels (CRP), white blood cell count (WBC), and absolute neutrophil count (ANC), were documented and inflammation indexes, e.g., neutrophil-lymphocyte ratio (NLR) and Platelet × CRP multiplier (PCM), were calculated. Tumor burden was determined using [68Ga]GaDOTATATE PET/CT before enrollment and every 2 cycles thereafter until progression. Therapy response was assessed using RECIST 1.1, including its volumetric modification. Inflammatory biomarkers and inflammatory indexes demonstrated marked heterogeneity among patients, and were significantly higher in non-responders (e.g., CRP (P < 0.001), ANC (P = 0.002), and PCM (P < 0.001)). Change in whole-body tumor burden after two cycles of PRRT was significantly associated with CRP (P = 0.0157) and NLR (P = 0.0040) in multivariate regression analysis. A cut-off of 2.5 mg/L for CRP (AUC = 0.84, P = 0.001) revealed a significant outcome difference between patients with adversely high vs. low CRP (median PFS 508 days vs. not yet reached (HR = 4.52; 95% CI, 1.27 to 16.18; P = 0.02)). Tumor-driven systemic inflammatory networks may be associated with treatment response, change in tumor burden, and prognosis in patients with GEPNETs receiving PRRT.

Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors

2018 ◽  
Vol 25 (12) ◽  
pp. 3613-3620 ◽  
Author(s):  
David Strosberg ◽  
Eric B. Schneider ◽  
Jill Onesti ◽  
Neil Saunders ◽  
Bhavana Konda ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Prognostic Impact

Impact of Mesenteric Mass in Patients With Midgut Neuroendocrine Tumors

Pancreas ◽  
2019 ◽  
Vol 48 (5) ◽  
pp. 682-685 ◽  
Author(s):  
Preeti Malik ◽  
Candida Pinto ◽  
Monica S. Naparst ◽  
Stephen C. Ward ◽  
Anne Aronson ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Mesenteric Mass

scholarly journals Survival of patients with appendiceal neuroendocrine tumors: whether they benefit from right hemicolectomy?

2020 ◽  
Author(s):  
Haiping Lin ◽  
Liyuan Wang ◽  
Yang Bai ◽  
Chenyang Ge ◽  
Hongjuan Zheng ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Neuroendocrine Tumors ◽  
Proportional Hazards ◽  
Proportional Hazards Model ◽  
Right Hemicolectomy ◽  
Prognostic Impact ◽  
Subdistribution Hazard ◽  
Survival Difference

Abstract Background: Current guidelines recommend right hemicolectomy for appendiceal neuroendocrine tumors (A-NETs) patients with lymph node (LN) metastasis. However, prognosis of these patients is favorable, and the prognostic impact of metastatic LN is controversial.Objective: The study aims to evaluate the prognostic factors of A-NETs, and explore whether right hemicolectomy/ more extended procedure (RHCM) improves prognosis compared to less extended than right hemicolectomy (LRHC).Methods: Patients with A-NETs were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The Fine-Gray proportional hazards model was established to calculate subdistribution hazard ratios of prognostic factors. A propensity score matching was performed to balance intergroup differences between the LRHC and RHCM groups, and survival difference between the after-matched groups was tested using the Gray test. Subgroup analyses were also conducted.Results: In the multivariate analysis, histological type and distant metastatic status were associated with prognosis, while tumor size and nodal status were not. After propensity score matching, the patients’ characteristics were well balanced. RHCM did not confer survival benefits in the whole after-matched patients or any subgroup.Conclusions: Metastatic LN does not significantly impact prognosis, and RHCM fails to improve prognosis compared to LRHC. Therefore, the current “LN-decided” surgical procedure may not be suitable for patients with A-NETs.

scholarly journals How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 514 ◽  
Author(s):  
Jacqueline Trouillas ◽  
Marie-Lise Jaffrain-Rea ◽  
Alexandre Vasiljevic ◽  
Gérald Raverot ◽  
Federico Roncaroli ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Early Recognition ◽  
Pituitary Tumors ◽  
Operative Management ◽  
Prognostic Impact ◽  
Null Cell ◽  
Ki 67 ◽  
Standardized Report ◽  
Proliferative Markers ◽  
Morphologic Type

Adenohypophyseal tumors, which were recently renamed pituitary neuroendocrine tumors (PitNET), are mostly benign, but may present various behaviors: invasive, “aggressive” and malignant with metastases. They are classified into seven morphofunctional types and three lineages: lactotroph, somatotroph and thyrotroph (PIT1 lineage), corticotroph (TPIT lineage) or gonadotroph (SF1 lineage), null cell or immunonegative tumor and plurihormonal tumors. The WHO 2017 classification suggested that subtypes, such as male lactotroph, silent corticotroph and Crooke cell, sparsely granulated somatotroph, and silent plurihormonal PIT1 positive tumors, should be considered as “high risk” tumors. However, the prognostic impact of these subtypes and of each morphologic type remains controversial. In contrast, the French five-tiered classification, taking into account the invasion, the immuno-histochemical (IHC) type, and the proliferative markers (Ki-67 index, mitotic count, p53 positivity), has a prognostic value validated by statistical analysis in 4 independent cohorts. A standardized report for the diagnosis of pituitary tumors, integrating all these parameters, has been proposed by the European Pituitary Pathology Group (EPPG). In 2020, the pituitary pathologist must be considered as a member of the multidisciplinary pituitary team. The pathological diagnosis may help the clinician to adapt the post-operative management, including appropriate follow-up and early recognition and treatment of potentially aggressive forms.

Prognostic impact of bone metastases detected by 18F-DOPA PET in patients with metastatic midgut neuroendocrine tumors

2020 ◽  
Author(s):  
Nicolas Deleval ◽  
Louise Pesque ◽  
Arnaud Dieudonné ◽  
Flore Viry ◽  
Olivia Hentic ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Neuroendocrine Tumors ◽  
Prognostic Impact

scholarly journals Prognostic impact of p16 and p21 on gastroenteropancreatic neuroendocrine tumors

2013 ◽  
Vol 6 (6) ◽  
pp. 1641-1645 ◽  
Author(s):  
SHUZHENG LIU ◽  
YUXI CHANG ◽  
JIE MA ◽  
XU LI ◽  
XIAOHONG LI ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Prognostic Impact ◽  
Gastroenteropancreatic Neuroendocrine Tumors
Sign in / Sign up

Export Citation Format

Share Document